The global bioinformatics services market size 2026 is on a strong growth trajectory. According to Fortune Business Insights, the market stood at USD 7.82 billion in 2026 and is projected to reach USD 22.03 billion by 2034, expanding at a compound annual growth rate (CAGR) of 13.83% during the forecast period. This remarkable growth is being fueled by the accelerating adoption of bioinformatics across genomics research, personalized medicine, and pharmaceutical drug discovery — alongside the rapid proliferation of cloud-based platforms that are lowering costs and improving accessibility for smaller institutions and research centers.
Key Market Drivers
1. Expanding Role in Personalized Medicine One of the most significant growth catalysts is the increasing demand for precision medicine. Bioinformatics plays a central role in analyzing genomic data to understand disease-causing gene mutations, enabling the development of customized treatments tailored to individual patients' genetic profiles.
2. Advances in Next-Generation Sequencing (NGS) Continuous technological improvements in sequencing — particularly NGS — have dramatically lowered the cost of genome sequencing. This cost reduction has accelerated the adoption of sequencing services across clinical and research settings, making high-throughput genomic analysis more accessible than ever before.
3. Drug Discovery and R&D Investment Pharmaceutical and biotechnology companies are increasingly leveraging bioinformatics to identify and validate drug targets by analyzing protein structures, genomic data, and biological pathways. This accelerates the drug discovery pipeline and enhances research efficiency, driving demand for outsourced bioinformatics expertise.
4. Cloud-Based Solutions The shift toward cloud-based platforms has enabled seamless data sharing, collaboration, and scalability — reducing the need for heavy upfront IT infrastructure. This has broadened market participation, especially among academic institutions and mid-sized biotech firms.
5. COVID-19 Impact During the pandemic, significant government and industry investment was directed toward analyzing genomic data related to COVID-19. Market players accelerated their R&D activities to provide effective bioinformatics solutions, generating a positive long-term impact on revenue streams.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/bioinformatics-services-market-109496
Market Segmentation
By Service Type: The sequencing services segment led the market in 2026 and is expected to retain the largest share throughout the forecast period. Widespread applications in genomics and personalized medicine, combined with the accelerating adoption of NGS technologies, are key reasons for this dominance.
By End User: End users span academic institutes and research centers, hospitals and clinics, pharmaceutical and biotechnology companies, and contract research organizations (CROs). Academic institutes and research centers are expected to witness the fastest growth, driven by growing focus on molecular biology, genomics research, and computational biology — supported by both government and private funding.
By Specialty: The medical biotechnology segment led the market in 2024, reflecting the heavy reliance on bioinformatics in clinical diagnostics, gene expression analysis, and biomarker detection.
Regional Insights
North America dominated the bioinformatics services market with a 45.87% share in 2025, valued at USD 2.99 billion. This leadership is attributed to a strong ecosystem of service providers, robust research infrastructure, substantial government funding for genomics, and early adoption of precision medicine approaches.
Europe is growing steadily, driven by rising clinical research funding, large-scale genomic sequencing initiatives, and advancements in personalized medicine.
Asia Pacific is emerging as the fastest-growing region. Countries like China and Japan are expanding rapidly — China through growth in clinical trials and big-data analytics, and Japan through integration of bioinformatics in pharmaceutical R&D and sequencing innovation.
Competitive Landscape
The bioinformatics services market is highly competitive, with key players including:
- Illumina, Inc. (U.S.)
- QIAGEN (Netherlands)
- Thermo Fisher Scientific Inc. (U.S.)
- Eurofins Scientific (Luxembourg)
- CD Genomics (U.S.)
- Fios Genomics (U.K.)
- Psomagen (U.S.)
- Creative Proteomics (U.S.)
- Excelra (U.S.)
Companies are actively pursuing partnerships, platform expansions, and acquisitions to strengthen their portfolios. For instance, QIAGEN's acquisition of Genoox (an AI-powered genomic analysis software company) underlines the industry trend of integrating artificial intelligence into bioinformatics workflows.
Future Outlook
The bioinformatics services market is poised for sustained expansion through 2034, shaped by the convergence of AI and machine learning with genomics, growing pharmaceutical outsourcing, and widening applications in agriculture, environmental science, and clinical diagnostics. The declining cost of sequencing technologies combined with the growth of cloud-native platforms is expected to make bioinformatics services increasingly accessible — broadening the market's base and accelerating adoption globally.